Latest Breaking News On - Accord healthcare ltd - Page 1 : comparemela.com

Paclitaxel Injection Global Market Report 2024 - Paclitaxel Injection Market to Reach $9 85 Billion by 2028

/PRNewswire/ The "Paclitaxel Injection Global Market Report 2024" has been added to ResearchAndMarkets.com s offering. The paclitaxel injection market size.

United statesUnited kingdomSouth koreaLaura woodNatco pharmaSagent pharmaceuticals incPanacea biotec ltdCancer research instituteLaboratories pvt ltdNational cancer instituteLuye pharma groupViatris incHetero drugs ltdIntas pharmaceuticals ltdAlembic pharmaceuticalsGland pharma

Global Caspofungin Market Projected to Hit USD 590 5

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) The

United statesAsia pacificEli lillyRoche ltdTeva pharmaceutical industries ltdGilead sciences incAstellas pharma incNovartis internationalAccord healthcare ltdEnzon pharmaceuticalsMerck coPfizer incTau pharmaceuticalsBristol myers squibbNorth americaMarket analysis

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara (Ustekinumab)

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara (Ustekinumab)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSeika pharmaIntas pharmaceuticalsDrug administrationAccord biopharma incJanssen biotech incIntas pharmaceuticals ltdDonga socio holdingsAccord healthcare ltdAccord biopharmaBiologics license applicationMarketing authorization applicationAccord healthcareSocio holdingsMeiji seika pharma

Capecitabine Market global production, growth, share, demand 2029

The Global Capecitabine Market is growing at a CAGR of 6.2% during forecasting period 2023-2029.

United statesAsia pacificTeva pharmaRoche ltdCipla incRxi pharmaceuticals incPerrigo companyAccord healthcare ltdResearch methodologyAvita medicalFresenius se coCompany overviewDr reddy laboratories ltdSandoz incMarket research is indiaReliance group

MHRA authorises enzyme inhibitor Anastrozole to prevent breast cancer in post-menopausal women

Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.

United kingdomDepartment of healthAccord healthcare ltdRegulatory agencyInternational breast cancer interventionYellow cardGoogle playApple appAccord healthcareProduct characteristicsPatient information